After eschewing venture capital for the better part of a decade, Watertown, Mass.-based FORMA Therapeutics is changing its tune.
The company, which has a lead drug candidate that takes aim at sickle cell disease, announced Thursday it had raised $100 million in a Series D financing round from a group of venture investors that includes RA Capital, Cormorant Capital, Wellington Management, and Samsara BioCapital, among others.
About the Author Reprints
